Related references
Note: Only part of the references are listed.Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma
Makoto Sumitomo et al.
CANCER SCIENCE (2021)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)
Borghaei
JOURNAL OF CLINICAL ONCOLOGY (2021)
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Induction of Pyroptosis: A Promising Strategy for Cancer Treatment
Lei Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Ilaria Attili et al.
LUNG CANCER (2021)
Bispecific Antibodies: From Research to Clinical Application
Jiabing Ma et al.
FRONTIERS IN IMMUNOLOGY (2021)
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
Simon Eschweiler et al.
NATURE IMMUNOLOGY (2021)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises
Kleita Michaelidou et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2020)
Determinants of Resistance to Checkpoint Inhibitors
Linda Tran et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Necroptosis in Immuno-Oncology and Cancer Immunotherapy
Jenny Sprooten et al.
CELLS (2020)
Mechanisms of Cancer Resistance to Immunotherapy
Rilan Bai et al.
FRONTIERS IN ONCOLOGY (2020)
The Resistance Mechanisms of Lung Cancer Immunotherapy
Fen Wang et al.
FRONTIERS IN ONCOLOGY (2020)
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
Laura Boyero et al.
CANCERS (2020)
The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
Marcin Nicos et al.
FRONTIERS IN ONCOLOGY (2020)
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy
Frank Cichocki et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression
Malene Stochkel Frank et al.
LUNG CANCER (2020)
Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?
Ivan Pourmir et al.
CANCER DRUG RESISTANCE (2020)
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
Simon Papillon-Cavanagh et al.
ESMO OPEN (2020)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
Lin Yu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Yoshihiro Ohue et al.
CANCER SCIENCE (2019)
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Urania Dafni et al.
LUNG CANCER (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
Orgilmaa Regzedmaa et al.
ONCOTARGETS AND THERAPY (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response
Christopher A. Hamm et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2019)
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
Hongge Liang et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Michael Offin et al.
JCO PRECISION ONCOLOGY (2019)
Global Epidemiology of Lung Cancer
Julie A. Barta et al.
ANNALS OF GLOBAL HEALTH (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Robert D. Leone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
Elizabeth Dudnik et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Determinants and clinical implications of chromosomal instability in cancer
Laurent Sansregret et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa et al.
NATURE REVIEWS CANCER (2018)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and immunotherapies
Geraldine Genard et al.
FRONTIERS IN IMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes
Patrick H. Lizotte et al.
JCI INSIGHT (2016)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Acquired and intrinsic resistance in cancer immunotherapy
Sander Kelderman et al.
MOLECULAR ONCOLOGY (2014)
The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
Hye-Jung Kim et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cancer-Related Inflammation
Juliana Candido et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase a type I signaling
Tatiana Raskovalova et al.
CANCER RESEARCH (2007)
Share Paper
